비교리스트

 카트 문의
시장보고서
상품코드
1462260

FYARRO 시장 : 시장 규모, 예측, 시장 인사이트(-2032년)

FYARRO Market Size, Forecast, and Market Insight - 2032
발행일: | 리서치사: DelveInsight | 페이지 정보: 영문 30 Pages | 배송안내 : 2-10일 (영업일 기준)

    
    
    




■ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송일정은 문의해 주시기 바랍니다.

FYARRO(주사제 실로리무스 단백질 결합 입자 현탁액)(알부민 결합)은 성인 환자의 절제불능 또는 전이성 국소 진행성 악성 흑색종 치료에 사용되는 처방약으로, 암세포와 싸우기 위해 고안되었습니다. 진행성 악성 PEComa에서는 혈관주위 상피세포가 통제할 수 없을 정도로 증식하는데, FYARRO는 암세포가 통제할 수 없을 정도로 증식하는 신호 중 하나를 차단하여 암세포의 증식과 전이를 막는 데 도움을 줍니다. 표적 암 치료이지 화학 요법이 아닌 표적 암 치료이며, FYARRO가 다른 mTOR 억제제와 다른 점은 나노입자 기술을 사용하여 종양 내에 더 많은 약물을 흡수하고 더 많은 mTOR 스위치를 끄는 데 도움이된다는 것입니다.

권장 용량은 100mg/m2이며, 21일 주기의 1일과 8일째에 30분 동안 정맥주사로 투여합니다.

FYARRO에 포함된 실로리무스는 mTOR(mechanism target of rapamycin kinase, 이전에는 mammalian target of rapamycin으로 알려짐)의 억제제입니다. K/ACT 경로의 다운스트림에 위치하며, 세포 생존, 성장, 증식과 같은 중요한 세포 과정을 조절하며, 일부 인간 암에서 일반적으로 발현이 조절됩니다. 세포 내에서 실로리무스는 FKBP-12(FK Binding Protein-12, FKBP-12)와 결합하여 면역 억제 복합체를 형성합니다. 실로리무스-FKBP-12 복합체는 라파마이신 복합체 1(mTORC1)에 결합하여 그 활성화를 억제합니다. 실로리무스의 mTOR 억제는 in vitro 및 in vivo 시험에서 세포 증식, 혈관 신생 및 포도당 섭취를 억제하는 것으로 나타났습니다.

앞으로 몇 년 동안 혈관주위상피세포종(PEComa)의 시장 시나리오는 전 세계적으로 광범위한 연구와 의료 지출 증가로 인해 변화할 것입니다.

회사들은 질병을 치료/개선하기 위한 새로운 접근 방식에 초점을 맞춘 치료법을 개발하고, 과제를 평가하고, FYARRO의 우위에 영향을 미칠 수 있는 기회를 모색하고 있습니다.

PEComa에 대한 다른 신흥 제품은 FYARRO에 치열한 시장 경쟁을 가져올 것으로 예상되며, 가까운 시일 내에 후발 신약이 출시되면 시장에 큰 영향을 미칠 것으로 보입니다.

규제 마일스톤과 개발 활동에 대한 자세한 설명은 PEComa에서 FYARRO의 현재 개발 시나리오를 제공합니다.

이 보고서는 주요 7개국의 혈관주위상피세포종 치료제 FYARRO 시장에 대해 조사했으며, 시장 개요, 경쟁 상황, 2032년까지의 시장 규모 예측, 국가별 시장 분석 등의 정보를 전해드립니다.

목차

제1장 보고서 소개

제2장 혈관주위상피세포종(PEComa)의 FYARRO 개요

  • 제품 상세
  • 임상 개발
    • 임상 연구
    • 임상시험 정보
    • 안전성과 유효성
  • 규제 마일스톤
  • 기타 발달 활동
  • 제품 프로파일

제3장 경쟁 상황(출시된 치료법)

제4장 경쟁 상황(후기 단계 새로운 치료법)

제5장 FYARRO 시장 평가

  • 혈관주위상피세포종(PEComa)의 FYARRO 시장 전망
  • 주요 7개국 분석
    • 주요 7개국의 혈관주위상피세포종(PEComa)의 FYARRO 시장 규모
  • 국가별 시장 분석
    • 미국
    • 독일
    • 영국

제6장 SWOT 분석

제7장 애널리스트의 견해

제8장 부록

제9장 DelveInsight의 서비스 내용

제10장 면책사항

제11장 DelveInsight 소개

제12장 보고서 구입 옵션

ksm 24.04.22

"FYARRO Market Size, Forecast, and Market Insight - 2032" report provides comprehensive insights about FYARRO for Perivascular Epithelioid Cell Neoplasm (PEComa) in the seven major markets. A detailed picture of the FYARRO for PEComa in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the FYARRO for PEComa. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the FYARRO market forecast analysis for PEComa in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in PEComa.

Drug Summary:

FYARRO (sirolimus protein-bound particles for injectable suspension) (albumin-bound) is a prescription medicine used to treat locally advanced unresectable or metastatic malignant PEComa in adult patients. FYARRO had been designed to fight cancer cells. In advanced malignant PEComa, perivascular epithelioid cells grow out of control. FYARRO blocks one of the signals in the cancer cells causing it to grow out of control, helping to stop cancer from growing or spreading. It is a targeted cancer treatment and not a chemotherapy treatment. FYARRO is different from other mTOR inhibitors because it uses nanoparticle technology to help FYARRO get more of the drug inside tumors to help turn more mTOR switches off.

The recommended dosage of FYARRO is 100 mg/m2 administered as an intravenous infusion over 30 minutes on Days 1 and 8 of each 21-day cycle until disease progression or unacceptable toxicity.

Mechanism of action

Sirolimus in FYARRO is an inhibitor of the mechanistic target of rapamycin kinase (mTOR, previously known as the mammalian target of rapamycin). mTOR, a serine-threonine kinase, is downstream of the PI3K/AKT pathway, controls key cellular processes such as cell survival, growth, and proliferation, and is commonly dysregulated in several human cancers. In cells, sirolimus binds to the immunophilin, FK Binding Protein-12 (FKBP-12), to generate an immunosuppressive complex. The sirolimus-FKBP-12 complex binds to and inhibits the activation of the mechanistic target of rapamycin complex 1 (mTORC1). Inhibition of mTOR by sirolimus has been shown to reduce cell proliferation, angiogenesis, and glucose uptake in vitro and in vivo studies.

Scope of the Report:

The report provides insights into:

  • A comprehensive product overview including the FYARRO description, mechanism of action, dosage and administration, research and development activities in Perivascular Epithelioid Cell Neoplasm (PEComa).
  • Elaborated details on FYARRO regulatory milestones and other development activities have been provided in this report.
  • The report also highlights the FYARRO research and development activities in PEComa across the United States, Europe and Japan.
  • The report also covers the patents information with expiry timeline around FYARRO.
  • The report contains forecasted sales of FYARRO for PEComa till 2032.
  • Comprehensive coverage of the late-stage emerging therapies for PEComa.
  • The report also features the SWOT analysis with analyst views for FYARRO in PEComa.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

FYARRO Analytical Perspective by DelveInsight

  • In-depth FYARRO Market Assessment

This report provides a detailed market assessment of FYARRO for Perivascular Epithelioid Cell Neoplasm (PEComa) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.

  • FYARRO Clinical Assessment

The report provides the clinical trials information of FYARRO for Perivascular Epithelioid Cell Neoplasm (PEComa) covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

  • In the coming years, the market scenario for Perivascular Epithelioid Cell Neoplasm (PEComa) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence FYARRO dominance.
  • Other emerging products for PEComa are expected to give tough market competition to FYARRO and launch of late-stage emerging therapies in the near future will significantly impact the market.
  • A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of FYARRO in PEComa.
  • Our in-depth analysis of the forecasted sales data of FYARRO from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the FYARRO in PEComa.

Key Questions:

  • What is the product type, route of administration and mechanism of action of FYARRO?
  • What is the clinical trial status of the study related to FYARRO in Perivascular Epithelioid Cell Neoplasm (PEComa) and study completion date?
  • What are the key collaborations, mergers and acquisitions, licensing and other activities related to the FYARRO development?
  • What are the key designations that have been granted to FYARRO for PEComa?
  • What is the forecasted market scenario of FYARRO for PEComa?
  • What are the forecasted sales of FYARRO in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
  • What are the other emerging products available and how are these giving competition to FYARRO for PEComa?
  • Which are the late-stage emerging therapies under development for the treatment of PEComa?

Table of Contents

1. Report Introduction

2. FYARRO Overview in Perivascular Epithelioid Cell Neoplasm (PEComa)

  • 2.1. Product Detail
  • 2.2. Clinical Development
    • 2.2.1. Clinical studies
    • 2.2.2. Clinical trials information
    • 2.2.3. Safety and Efficacy
  • 2.3. Regulatory Milestones
  • 2.4. Other Developmental Activities
  • 2.5. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. FYARRO Market Assessment

  • 5.1. Market Outlook of FYARRO in Perivascular Epithelioid Cell Neoplasm (PEComa)
  • 5.2. 7MM Analysis
    • 5.2.1. Market Size of FYARRO in the 7MM for Perivascular Epithelioid Cell Neoplasm (PEComa)
  • 5.3. Country-wise Market Analysis
    • 5.3.1. Market Size of FYARRO in the United States for Perivascular Epithelioid Cell Neoplasm (PEComa)
    • 5.3.2. Market Size of FYARRO in Germany for Perivascular Epithelioid Cell Neoplasm (PEComa)
    • 5.3.3. Market Size of FYARRO in France for Perivascular Epithelioid Cell Neoplasm (PEComa)
    • 5.3.4. Market Size of FYARRO in Italy for Perivascular Epithelioid Cell Neoplasm (PEComa)
    • 5.3.5. Market Size of FYARRO in Spain for Perivascular Epithelioid Cell Neoplasm (PEComa)
    • 5.3.6. Market Size of FYARRO in the United Kingdom for Perivascular Epithelioid Cell Neoplasm (PEComa)
    • 5.3.7. Market Size of FYARRO in Japan for Perivascular Epithelioid Cell Neoplasm (PEComa)

6. SWOT Analysis

7. Analysts' Views

8. Appendix

  • 8.1. Bibliography
  • 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options

비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제